Table 2.
Clinical status of participants.
| Item | All participants(N = 2158) | Intention to receive COVID-19 vaccine | ||
|---|---|---|---|---|
| Vaccine hesitancy(n = 519) | Vaccine acceptance(n = 1639) | P value | ||
| Type of cancer | < 0.001 | |||
| Head and neck cancer | 203 (9.41%) | 44 (8.48%) | 159 (9.70%) | |
| Respiratory and thoracic cancer | 579 (26.83%) | 136 (26.20%) | 443 (27.03%) | |
| Digestive tract cancer | 703 (32.58%) | 194 (37.38%) | 509 (31.06%) | |
| Urogenital caner | 136 (6.30%) | 25 (4.82%) | 111 (6.77%) | |
| Gynecologic cancer | 325 (15.06%) | 84 (16.18%) | 241 (14.70%) | |
| Other type of cancer | 152 (7.04%) | 15 (2.89%) | 137 (8.36%) | |
| Multiple types of cancer | 60 (2.78%) | 21 (4.05%) | 39 (2.38%) | |
| Time since cancer diagnosis (year) | 0.002 | |||
| < 1 | 1085 (50.28%) | 223 (42.97%) | 862 (52.59%) | |
| ≥ 1, < 3 | 692 (32.07%) | 192 (36.99%) | 500 (30.51%) | |
| ≥ 3, < 5 | 186 (8.62%) | 52 (10.02%) | 134 (8.18%) | |
| ≥ 5 | 195 (9.04%) | 52 (10.02%) | 143 (8.72%) | |
| Ongoing treatment | < 0.001 | |||
| None | 176 (8.16%) | 17 (3.28%) | 159 (9.70%) | |
| Surgery* | 420 (19.46%) | 63 (12.14%) | 357 (21.78%) | |
| Radiotherapy | 82 (3.80%) | 17 (3.28%) | 65 (3.97%) | |
| Chemotherapy | 330 (15.29%) | 77 (14.84%) | 253 (15.44%) | |
| Immunological and molecular-targeted therapy | 67 (3.10%) | 15 (2.89%) | 52 (3.17%) | |
| Traditional Chinese medicine | 144 (6.67%) | 43 (8.29%) | 101 (6.16%) | |
| Other therapy | 20 (0.93%) | 3 (0.58%) | 17 (1.04%) | |
| Multiple therapies | 919 (42.59%) | 284 (54.72%) | 635 (38.74%) | |
| Family history of cancer | 0.005 | |||
| No | 1895 (87.81%) | 437 (84.20%) | 1458 (88.96%) | |
| Yes | 263 (12.19%) | 82 (15.80%) | 181 (11.04%) | |
| Complication | 0.736 | |||
| No | 1797 (83.27%) | 435 (83.82%) | 1362 (83.10%) | |
| Yes | 361 (16.73%) | 84 (16.18%) | 277 (16.90%) | |
| Metastasis | 0.001 | |||
| No | 1609 (74.56%) | 358 (68.98%) | 1251 (76.33%) | |
| Yes | 549 (25.44%) | 161 (31.02%) | 388 (23.67%) | |
Data are presented as number (percentage). P values were calculated via chi-squared tests between the “vaccine hesitancy” and “vaccine acceptance” groups. Participants who had received or were willing to receive the COVID-19 vaccine were included in the “vaccine acceptance” group, and those who had not received or were unwilling to receive the COVID-19 vaccine were included in the “vaccine hesitancy” group. * Surgery including procedures such as excision, transarterial chemoembolization, and microwave ablation. COVID-19: coronavirus disease 2019.